Eleven years ago, Eliana Nachem’s life seemed to be marked by a never-ending battle with germs. As an infant, she was diagnosed with severe combined immunodeficiency (SCID), a rare and devastating condition that leaves children without a functional immune system. For Eliana, exposure to even the most benign germs could have been fatal. But thanks to a pioneering gene therapy treatment, Eliana is now living a normal, active life—free from the sterile, isolated existence that defined her early years.
Eliana’s remarkable recovery and the breakthrough gene therapy that made it possible were highlighted in a recent study published in the New England Journal of Medicine. The study revealed that gene therapy for children with ADA-SCID, a specific form of SCID caused by a missing enzyme, was successful in 95% of the participants. Eliana, who was enrolled in the clinical trial as a baby, is one of the success stories from this life-changing treatment.
A Life in Isolation: The Early Years of Eliana Nachem
When Eliana was just two months old, her parents, Jeff and Caroline Nachem, noticed that their baby girl had a persistent cough. A few weeks later, Eliana began experiencing severe gastrointestinal issues, which prompted a visit to their pediatrician. But what initially seemed like a common illness soon became a harrowing diagnosis: Eliana had ADA-SCID, a rare genetic disorder that impacts the immune system by preventing the production of T-cells and B-cells—critical components required to fight infections.
At just four months old, Eliana’s diagnosis was confirmed. For the Nachems, the news was devastating. Children born with SCID typically do not survive beyond their second birthday unless treated, and the prognosis for Eliana seemed grim. Without a functioning immune system, every exposure to even the most common germs posed a life-threatening risk. The Nachems quickly took action, converting their home into a germ-free sanctuary to protect Eliana. They rehomed their pets, kept the windows closed, and ensured that visitors adhered to strict protocols, wearing gloves, gowns, and masks whenever they entered the house.
Despite the overwhelming challenges, Eliana’s parents found solace in research. As they searched for potential treatments, they discovered a clinical trial in Los Angeles that offered hope—a gene therapy for ADA-SCID that could restore her immune system and, potentially, give her the chance at a normal life.
The Breakthrough Gene Therapy: A Game Changer for SCID Treatment
In 2014, at just 10 months old, Eliana was enrolled in the clinical trial for ADA-SCID, one of the first of its kind. Led by Dr. Donald Kohn, a pediatric bone marrow transplant physician at UCLA’s Broad Stem Cell Research Center, the trial aimed to test the efficacy of a gene therapy developed to treat ADA-SCID by correcting the genetic mutation responsible for the condition.
The treatment involved harvesting stem cells from Eliana’s own bone marrow and then modifying them in a laboratory. Using an inactivated version of the HIV virus, researchers introduced the missing ADA gene into the stem cells. The modified cells were then reinfused into Eliana’s body after she underwent chemotherapy to make room for the new cells. Over the course of a year, the stem cells began to divide and generate a healthy immune system that no longer required the missing ADA enzyme.
Eliana’s body slowly began to rebuild its immune function, and, as time went on, she became healthier and stronger. By the end of the trial, Eliana’s immune system had been fully restored, with no need for additional treatments or medications. Today, 95% of the trial participants, including Eliana, have experienced similar success, a triumph in the field of gene therapy for genetic diseases.
Why Gene Therapy is a Safer Alternative to Bone Marrow Transplants
Prior to the advent of gene therapy, the standard treatment for children with SCID was a bone marrow transplant. However, this method carries significant risks. Bone marrow transplants typically require a donor who matches the patient’s genetic makeup. Unfortunately, only a small percentage of children have a sibling who is a perfect match, and finding a suitable non-related donor can be challenging.
Even when a donor match is found, the patient’s immune system is at risk of attacking the transplanted cells, leading to a condition called graft-versus-host disease. To prevent this, patients must take immunosuppressive drugs, which weaken their immune systems and slow the healing process. Moreover, the higher doses of chemotherapy required for bone marrow transplants can have long-term effects on a child’s growth, fertility, and overall health.
Gene therapy, on the other hand, eliminates many of these risks. Because the stem cells are harvested from the patient’s own body, the likelihood of immune rejection is significantly reduced. Additionally, the chemotherapy required for gene therapy is much lower, making it a safer and less invasive option with fewer long-term side effects.
Eliana’s Journey: From Isolation to Normalcy
Today, Eliana is a healthy and active 12-year-old girl who enjoys dancing, swimming, and playing on the playground with her friends—activities that would have been unthinkable just a few years ago. Before the gene therapy, Eliana lived in near-total isolation, unable to interact with others or even go outside due to the constant risk of infection. Now, she is able to experience life like any other child her age.
“It’s amazing that she was able to go from living in isolation to being able to go to preschool and go swimming in a public pool and play on a playground and do all the things that every other kid gets to do,” said Jeff Nachem, Eliana’s father.
Though Eliana is thriving, she still undergoes regular check-ups to ensure her immune system remains healthy. Twice a year, she undergoes testing to monitor the status of her immune function, but so far, her progress has been excellent. “We think it’s a lifelong therapy,” said Dr. Donald Kohn, the trial’s lead investigator. “Some of these kids are now 15 years old and are living normal lives.”
Hope for the Future: Gene Therapy as a Standard of Care
The success of this gene therapy trial has significant implications not only for children with ADA-SCID but also for other rare diseases that have yet to see effective treatments. As the data from this trial continues to inspire hope, researchers are optimistic that gene therapies could eventually become the standard of care for ADA-SCID and other genetic disorders.
Dr. Talal Mousallem, an associate professor at Duke University School of Medicine, praised the results of the trial, calling it one of the most successful gene therapy trials for an ultra-rare genetic disease. He hopes the success of this trial will pave the way for gene therapies to be developed for other forms of SCID, as well as other genetic diseases that have long been overlooked.
For Eliana and her family, this groundbreaking treatment has not only restored her immune system but also allowed her to live a full, healthy life. As Eliana continues to thrive, her story stands as a testament to the life-changing potential of gene therapy in treating genetic disorders.
